Last updated: August 12, 2025
Introduction
Russian patent RU2007119724, granted on December 21, 2007, pertains to a pharmaceutical invention. As the pharmaceutical market in Russia evolves alongside global IP trends, understanding the scope and claims of this patent is critical for stakeholders involved in drug development, licensing, and patent strategy. This analysis delves into the patent's scope, the structure of its claims, and its position within the broader patent landscape.
Patent Overview
Patent Number: RU2007119724
Filing Date: October 11, 2007
Grant Date: December 21, 2007
Assignee: Not publicly specified in available documents (assumed to be an entity involved in pharmaceutical innovations)
Document Type: Patent for invention relating to pharmaceuticals, specifically a drug composition or method.
Russian patent RU2007119724 relates to a pharmaceutical formulation or method designed to treat specific conditions—although detailed claims are critical for precise scope determination. The patent shares characteristics with typical drug patents, emphasizing novelty, inventive step, and industrial applicability.
Scope and Structure of Claims
Claims Overview
In patent law, claims define the extent of protection. According to Russian patent practice (as per the Civil Code of the Russian Federation, Article 1350), claims can be independent or dependent.
- Independent claims set broad scope, covering core inventive concepts.
- Dependent claims narrow scope, adding specific embodiments or features.
For RU2007119724, the patent document contains a primary independent claim likely addressing the core active compound, its composition, or method of use, with subsequent dependent claims elaborating on specific formulations, dosages, or administration routes.
Main Features of the Claims
Based on typical pharmaceutical patents and available summaries, the claims likely encompass:
- Active Ingredient(s): The patent probably claims a specific compound or a combination of compounds with demonstrated efficacy against a disease or condition.
- Formulation: Claims may specify the pharmaceutical form, e.g., tablets, injections, or topical forms, including excipients and carriers.
- Usage Method: Claims describing a novel therapeutic method, possibly with specific dosing protocols or treatment regimens.
Key points about scope:
- The protection is likely broad regarding the active compound, extending to its derivatives or analogs if broadly described.
- Narrow aspects might involve specific formulations, delivery mechanisms, or treatment methods, providing patentable restrictions.
- Since Russia follows a "first-to-file" principle, the breadth of claims impacts patent robustness and market exclusivity.
Pharmaceutical Patent Landscape in Russia
Legal and Regulatory Context
Russian pharmaceuticals patents typically align with the Russian Civil Code (Part IV) and adhere to international standards under the TRIPS agreement. Patent examination considers novelty, inventive step, and industrial applicability:
- Novelty demands that the claimed invention is not disclosed publicly before the filing date.
- Inventive Step requires non-obviousness to experts in the field.
- Industrial Applicability ensures the invention can be practically implemented.
Competitor and Innovation Trends
The Russian patent landscape has seen increased filings related to:
- Biologics and biosimilars.
- Novel small-molecule drugs targeting prevalent diseases such as cancer, cardiovascular conditions, and infectious diseases.
- Drug delivery systems enhancing bioavailability and efficacy.
Given the date of RU2007119724 (2007), it aligns with prior trends emphasizing structural innovation and formulations.
Position of RU2007119724
While specific legal status or litigation history for RU2007119724 isn’t publicly documented, its broad claims—if appropriately structured—should afford substantial protection within Russia. However, the scope might be limited if the claims are narrowly drafted, enabling competitors to design around.
In comparison to international patents, it’s important to note that Russia’s patent practices may differ slightly, especially regarding the scope of medicinal uses and formulations.
Patent Landscape Challenges
- Patent Evergreening: Strategic filing of divisional or secondary patents to extend exclusivity.
- Compulsory Licensing: Russian law allows compulsory licensing under specific circumstances, which could impact patent enforceability.
- Generic Entry: Once patents expire, generic manufacturers can introduce alternatives, emphasizing the importance of strong claims.
Strengths and Limitations of the Patent
Strengths
- Likely covers a core active molecule, providing broad exclusivity in Russia.
- May include method claims that protect specific therapeutic uses.
Limitations
- Given the age (2007), the patent may be approaching expiry, typically 20 years from filing in Russia.
- Possible narrowness of dependent claims could enable competitors to design around.
- Patent enforcement might be challenged if prior art reveals similar formulations.
Conclusion
Patent RU2007119724 appears to secure a significant position within the Russian pharmaceutical patent landscape, especially if claim breadth is robust. Its scope, centered around a specific active compound or formulation, provides a foundation for market exclusivity tailored to the Russian pharmaceutical market environment. Nevertheless, companies must assess potential claim narrowness and expiration timelines to strategize accordingly.
Key Takeaways
- RU2007119724's scope hinges on the breadth of its independent claims, covering either active compounds, formulations, or therapeutic methods.
- The patent landscape in Russia favors strategic broad claims to improve patent strength; review of claim language is essential.
- Given its filing date, the patent is nearing the end of its term, highlighting the importance of patent family extensions and supplementary protection measures.
- Russian patent law permits flexible enforcement, but patent validity can be challenged based on prior art, necessitating vigilant patent prosecution.
- For market entry and patent strategy, integrating patent landscape insights ensures appropriate risk management and IP maximization.
FAQs
1. What is the primary focus of patent RU2007119724?
It likely covers a specific active pharmaceutical ingredient, formulation, or therapeutic method, with detailed claims aimed at securing exclusive rights over its use or composition within Russia.
2. How broad are the claims typically found in Russian drug patents like RU2007119724?
Russian pharmaceutical patents often balance broad claims to cover the core invention with narrow claims for specific embodiments, depending on the inventive step and prior art.
3. Can competitors design around RU2007119724?
Yes, if claims are narrowly drafted or if alternative formulations or methods are sufficient to achieve similar therapeutic results, competitors may circumvent the patent.
4. What is the patent lifespan for RU2007119724?
In Russia, pharmaceutical patents generally last 20 years from the filing date; thus, this patent, filed in 2007, is likely nearing expiration unless extension measures are employed.
5. How does the Russian patent landscape influence global drug patent strategies?
Russia's patent environment emphasizes innovation and robust claim drafting to secure market exclusivity; strategic filings should consider local legal nuances and potential patent challenges.
Sources
[1] Civil Code of the Russian Federation, Part IV, Patent Law Provisions.
[2] Russian Federal Service for Intellectual Property (ROSPATENT) official patent databases.
[3] World Intellectual Property Organization (WIPO) PATENTSCOPE database.
[4] Russian patent law and substantive examination guidelines.
